- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05114525
Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer
October 29, 2021 updated by: Stanford University
The purpose of this study is to conduct a descriptive feasibility study of assessing how patients retain and understand information regarding radiation therapy obtained from an initial consult visit.
This study will also pilot the use of visual aids and assess their utility to patients during a consult.
The study will provide a baseline to conduct larger studies that will later incorporate additional patient education tools to assess changes in patient understanding of information received in radiation oncology patient consultations.
Study Overview
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients 18 years or older with non-invasive or invasive breast cancer receiving consultation at the breast radiation oncology clinic for radiotherapy recommendations
Exclusion Criteria:
- Patients under 18 years old or receiving palliative care
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients Who are Anticipated to Receive Definitive Treatment
|
The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
post-consultation telephone questionnaire
Time Frame: 10 days
|
assess patient understanding and use of visual aids specifically in radiation oncology consultations
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
correlations between patient survey score as a measure of patient understanding
Time Frame: 10 days following consultation
|
Patients will also be asked to rate the ease of understanding of visual aids provided and their utility in facilitating patient understanding of radiation oncology concepts.
It will be analyzed via ANOVA to investigate the association of various factors to the patient's total score.
Each participant's interview will be scored based on the following scoring system: Correct"=1point; "Incorrect" = 0 point.
|
10 days following consultation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kathleen Horst, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2021
Primary Completion (Actual)
October 12, 2021
Study Completion (Actual)
October 12, 2021
Study Registration Dates
First Submitted
October 29, 2021
First Submitted That Met QC Criteria
October 29, 2021
First Posted (Actual)
November 10, 2021
Study Record Updates
Last Update Posted (Actual)
November 10, 2021
Last Update Submitted That Met QC Criteria
October 29, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-58571
- BRS0122 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Survey questionnaire
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Mbarara University of Science and...Completed
-
M.D. Anderson Cancer CenterCompleted
-
Frederiksberg University HospitalTerminated
-
First Affiliated Hospital of Wenzhou Medical UniversityQilu Hospital of Shandong University; Eastern Hepatobiliary Surgery Hospital; The First Affiliated Hospital of Zhejiang Chinese Medical UniversityEnrolling by invitationEfficacy | Liver Cancer | Adverse Event | Microbiota | PrognosisChina
-
Second Affiliated Hospital, School of Medicine,...Enrolling by invitation
-
Samsung Medical CenterActive, not recruitingOccupational Diseases | Emergency DepartmentsKorea, Republic of
-
Peking University Third HospitalCompleted
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)UnknownGlioma | Brain TumorUnited States, Finland, Sweden, Denmark, Israel, United Kingdom
-
M.D. Anderson Cancer CenterCompleted